

Billing & Coding Guide

- Coverage, Coding, & Payment for MONJUVI
- ▶ Best Practices for Timely Claims Reimbursement
- Example Claims Forms: CMS-1500 & CMS-1450
- Provider Readiness-Process and Tips
- ▶ IncyteCARES for MONJUVI-Patient Support Program Overview

This Billing and Coding Guide is intended to provide an overview of coding and coverage information for MONJUVI. Please use this guide to support the reimbursement process and as a source of information on IncyteCARES for MONJUVI.

While this guide provides information on navigating the reimbursement process, please note all enclosed coding information is for reference purposes only and is not intended to serve as guidance for specific coding, billing, and claims submissions. Decisions on which codes best describe the services provided must be made by individual providers based on specific payer guidance and requirements.

Incyte cannot guarantee payment of any claim and providers should contact third-party payers for specific information on their coding, coverage, and payment policies as needed.



For questions regarding MONJUVI reimbursement and access, please call IncyteCARES at 1-855-452-5234, M-F, 8 AM to 8 PM ET





Coverage, Coding, & Payment for MONJUVI

Coverage and payment methodology for MONJUVI will vary by payer type

For Medicare patients, MONJUVI will be covered under Medicare Part B when used for an FDA-approved indication and when medically reasonable and necessary.

There are no prior authorization requirements for MONJUVI under traditional fee-for-service Medicare plans.

For patients enrolled in a commercial health plan, Medicare Advantage, or Medicaid, coverage of MONJUVI will vary by payer. Some payers may also apply utilization restrictions for MONJUVI. When seeking coverage, providers should be prepared for the possibility of needing to go through the prior authorization process.

Payment Methodology



MEDICARE

Standard Medicare Part B reimbursement is average sales price (ASP) + 6%.*



COMMERCIAL PAYERS & MEDICAID

Drug reimbursement will vary by payer but is generally the contracted reimbursement rate between the payer and provider.

Incyte cannot guarantee payment of any claim and providers should contact third-party payers for specific information on their coding, coverage, and payment policies as needed.

*If Medicare sequestration is in effect, a statutory reduction to the payment is applied. Please visit CMS.gov for more information.

INDICATIONS & USAGE



Follicular Lymphoma

MONJUVI (tafasitamab-cxix), in combination with lenalidomide and rituximab, is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL).

<u>Limitations of Use</u>: MONJUVI is not indicated and is not recommended for the treatment of patients with relapsed or refractory marginal zone lymphoma outside of controlled clinical trials.

IMPORTANT SAFETY INFORMATION

Contraindications:

None.

Warnings and Precautions:

- Infusion-Related Reactions (IRRs). MONJUVI (tafasitamab-cxix) can cause IRRs, including fever, chills, rash, flushing, dyspnea, and hypertension. Premedicate patients and monitor frequently during infusion. Based on the severity of the IRR, interrupt or discontinue MONJUVI and institute appropriate medical management.
- Myelosuppression. MONJUVI can cause serious or severe myelosuppression, including neutropenia, lymphopenia, thrombocytopenia, and anemia. Monitor complete blood counts (CBCs) before each treatment cycle and throughout treatment. Monitor patients with neutropenia for signs of infection. Consider granulocyte colony-stimulating factor administration. Withhold MONJUVI based on the severity of the adverse reaction. Refer to the lenalidomide prescribing information for dosage modifications.
- Infections. Fatal and serious infections, including opportunistic infections, occurred in patients during treatment with MONJUVI and following the last dose. Among 274 patients with FL who received MONJUVI in combination with lenalidomide and rituximab in inMIND, Grade 3 or higher infections occurred in 24%. Monitor patients for signs and symptoms of infection and manage infections as appropriate. Consider infection prophylaxis per institutional quidelines. Consider treatment with subcutaneous or intravenous immunoglobulin (IVIG) as appropriate.



Coverage, Coding, & Payment for MONJUVI (CONT'D)

Please refer to the coding information below to support appropriate claims processing for MONJUVI for the treatment of follicular lymphoma (FL). Payer requirements for coding may vary. For the most accurate list of codes and billing requirements, please confirm with the individual payer.

		10-Digit	11-Digit
200 mg		50881-013-03	50881- 0 013-03
HCPCS Coding			
J9349	Injection, tafasitamal	o-cxix, 2 mg	
HCPCS Modifiers			
JZ	Zero drug amount o	discarded/not administered	to any patient
JW	Drug amount waste	d/discarded units	
ICD-10-CM Diagnosis C	codes		
C82.00 - C82.09	Follicular lymphoma g	rade I	

ICD-10-CM Diagnosis Code.	
C82.00 - C82.09	Follicular lymphoma grade I
C82.10 - C82.19	Follicular lymphoma grade II
C82.20 - C82.29	Follicular lymphoma grade III
C82.30 - C82.39	Follicular lymphoma grade IIIa
C82.50 - C82.59	Diffuse follicle center lymphoma
C82.60 - C82.69	Cutaneous follicle center lymphoma
C82.80 - C82.89	Other types of follicular lymphoma
C82.90 - C82.9	Follicular lymphoma, unspecified

Revenue	Codes		
Administr	ration	Drug	
0335	Chemotherapy Administration - IV	0636	Drugs requiring detailed coding

Drug Administration / CPT® Code

NDC

96413 Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial drug

CPT®, Current Procedural Terminology; HCPCS, Healthcare Common Procedure Coding System; ICD-10-CM, International Classification of Diseases, Tenth Revision, Clinical Modification; NDC, National Drug Code.



| Best Practices for Timely Claims Reimbursement

MONJUVI has a unique J-Code

J9349

Injection, tafasitamab-cxix, 2 mg

One single-dose vial of MONJUVI contains 200 mg of tafasitamab-cxix, equal to 100 billing units when using HCPCS code J9349.



Payer requirements regarding detailed claim form information may vary. It is important to check with individual payers on their specific requirements and ensure accurate documentation of services and units of measure.

For an efficient claims and reimbursement process, employ the following strategies:

- Verify accuracy of patient information
- ▶ **Use the MONJUVI specific J-code:** J9349 (Injection, tafasitamab-cxix, 2 mg) when completing a claim
- ▶ Ensure accurate coding: Refer to the MONJUVI Billing & Coding Guide for appropriate codes and modifiers
 - Reference the included example claims forms for guidance on accurately recording appropriate codes and supplemental information
- ▶ Include correct number of units administered. Note: One 200 mg single-dose vial is equal to 100 billing units
- Include correct modifier
 - To report no product discarded record the JZ Modifier on the same line as the HCPCS code
 - To report product wastage record the JW Modifier on a second claim line
- ▶ Ensure accuracy of information needed to process the claim
 - Correct NDC format use 10- or 11-digit format based on payer requirements
 - Prior authorization number, if applicable
- Check your payer agreements to ensure you understand any specific reimbursement needs for MONJUVI and follow the payer's recommendations for providing additional information (eg, medical records)
- ▶ Make sure electronic claims are successfully submitted
- Stay up to date with payer coverage policies

CPT®, Current Procedural Terminology; HCPCS, Healthcare Common Procedure Coding System; ICD-10-CM, International Classification of Diseases, Tenth Revision, Clinical Modification; NDC, National Drug Code.



For questions regarding billing, coding, or reimbursement for MONJUVI, call IncyteCARES to be connected with a Field Access Manager **1-855-452-5234**, M-F, 8 AM to 8 PM ET



The information herein is provided for educational purposes only. Insurance coverage and reimbursement are not guaranteed. Coverage and reimbursement may vary significantly by payer, plan, patient, and setting of care. It is the sole responsibility of the healthcare provider to select the proper codes and ensure the accuracy of all statements used in seeking coverage and reimbursement for an individual patient.



Using the JW & JZ Modifiers for Accurate Claims

It is important to use the correct modifier to reflect any wastage

The JW and JZ modifiers are HCPCS Level II modifiers used for claims that bill for single-dose container drugs. Improper use or omission of the JW and JZ modifiers may result in returned claims, requiring resubmission.

While MONJUVI is distributed in a single-dose vial, its dosage is based on the patient's weight, which may result in leftover medication that must be discarded but is eligible for payment under the discarded drug policy. In these cases, the JW modifier is used to report wastage. When using the JW modifier to bill for discarded drugs, the amount administered should be rounded up to the next billing unit.

In the event there is no wastage, the JZ modifier is used to indicate that no amount of drug was discarded or eligible for payment.

JW Modifier: Reporting Wastage

JZ Modifier: Documenting No Wastage

Two claim lines will be used:

J9349

1

I be used:

Use a single claim line:

No Modifier

Units Administered

1 J9349

JZ N

JZ Modifier Units Administered

2 **J9349** JW Modifier Units Wasted

Example 1: 40 kg patient

Administered 12 mg/kg of MONJUVI, equal to 480 mg of MONJUVI, drawn from **three** 200 mg single-use vials. **In this example, the JW modifier is used to report 120 mg (3 mL) of wastage on the CMS-1500 Claim Form.**

24. <i>A</i>	. DA From DD		OF SERV	ICE To DD	YY	B. PLACE OF SERVICE	C. EMG	D. PROCEDURE (Explain Un CPT/HCPCS		s)	E. DIAGNOSIS POINTER	F. \$ CHAF	IGES	G. DAYS OR UNITS	H. EPSDT Family Plan	I. ID. QUAL.	J. RENDERING PROVIDER ID. #
N47	353520	0801 N	/L 12.0)													
MM	DD	ΥY	MM	DD	ΥY	11		J9349				\$\$		240		NPI	
N47	353520	0801 N	/L 3.0														
MM	DD	ΥY	MM	DD	ΥY	11		J9349	JW			\$\$		60		NPI	

Example 2: 70 kg patient

Administered 12 mg/kg of MONJUVI, equal to 840 mg of MONJUVI, drawn from **five** 200 mg single-use vials. **In this example, the JW modifier is used to report 160 mg (4 mL) of wastage on the CMS-1450 Claim Form.**

	42 REV. CD.	43 DESCRIPTION	44 HCPCS / RATE / HIPPS CODE	45 SERV. DATE	46 SERV. UNITS	47 TOTAL CHARGES	48 NON-COVERED CHARGES	49	
1	0636	N47353520801 ML21.0	J9349	MM-DD-YY	420	\$\$			1
2									2
3	0636	N47353520801 ML4.0	J9349 - JW	MM-DD-YY	80	\$\$			3

Example 3: 50 kg patient

Administered 12 mg/kg of MONJUVI, equal to 600 mg of MONJUVI, drawn from **three** 200 mg single-use vials. **In this example, the JZ modifier is reported to denote no drug was discarded on the CMS-1450 Claim Form.**

	42 REV. CD.	43 DESCRIPTION	44 HCPCS / RATE / HIPPS CODE	45 SERV. DATE	46 SERV. UNITS	47 TOTAL CHARGES	48 NON-COVERED CHARGES	49	
1	0636	N47353520801 ML15.0	J9349 - JZ	MM-DD-YY	300	\$\$			1

Inclusion of the JZ or JW modifier is required for timely reimbursement and approval of claims.



Questions? Contact your Field Access Manager or call IncyteCARES for MONJUVI at **1-855-452-5234**, M-F, 8 AM to 8 PM ET



CPT®, Current Procedural Terminology; HCPCS, Healthcare Common Procedure Coding System.



MONJUVI Example CMS-1500 Claim Form

Physician Office Setting

This example form is provided for guidance and reference only.

MONJUVI and the associated services delivered by non-institutional providers in a physician office setting are billed on the CMS-1500 Claim Form. It is always the provider's responsibility to determine the appropriate healthcare setting and to submit true and correct claims for the products and services rendered. Incyte cannot guarantee payment of any claim and providers should contact third-party payers for specific information on their coding, coverage, and payment policies as needed.

Box 19

Some payers may require additional information for proper processing. This may include*: drug name, strength, route of administration, dosage administered, and NDC

Box 21

Enter the ICD-10-CM diagnosis code

Box 24 A-B

Enter the date of service and appropriate place of service code. If NDC reporting is required, include the following in the shaded portion of Box 24A*: N4+11-Digit NDC+ML+Unit quantity administered

Box 24 D

Enter the appropriate HCPCS, modifier, and CPT® codes. For example:

- Drug J9349 (Injection, tafasitamab-cxix, 2 mg)
- Modifier
 - JZ (include the JZ modifier on the same line as the HCPCS code to indicate no amount of drug was discarded)
 - JW (include the JW modifier on a separate line as the HCPCS code to indicate amount of drug discarded)
- Administration 96413 (Chemo infusion for first hour, single or initial drug)

Box 24 E

Refer to the diagnosis (Box 21), relating to the drug or procedure listed in Box 24D

Box 24 G

Enter number of units for each line item

- ▶ J9349 billing unit = 2 mg
- ▶ Single-dose vial = 200 mg
- ▶ 200 mg vial = 100 units

1. MEDICA		ONAL UI				/I FOI TTEE (N	UGC) 02/12													
MEDICA																				PICA [
(Medical	_	MEDIC (Medical	_	_	CARE (/DoD#)	Г	CHAMP\ (Member)	/A ID#)	GROUP HEALTH PL (ID#)	LAN CO	ECA SLK LUNG (D#)	OTHER (ID#)	1a. INSURED	'S I.D. NU	MBER			(For F	rogram ir	iltem 1)
2. PATIENT	NAME	(Last Na	me, Firs	t Name	, Middle	Initial)		3. PATI	ENT'S BIRT	гн рате		SEX F	4. INSURED'S	NAME (I	Last Nam	ne, First I	Name, M	Vliddle I	nitial)	
5. PATIENT	S ADDRI	SS (No	, Street)					6. PATI	ENT RELAT		M TO INSU		7. INSURED'S	ADDRES	SS (No.,	Street)				
CITY							STATE	Sett	Spous ERVED FOR		-	Other	CITY						Te.	TATE
									LITTLE	1110000	OL.									
ZIP CODE			TEI (LEPHO	NE (Incli	ude Area	Code)						ZIP CODE			TELE (PHONE	(Includ	le Area Cr	ode)
9. OTHER IN	SURED'	S NAME	(Last N	ame, Fi	rst Nami	e, Middle	Initial)	10, IS F	ATIENT'S C	CONDITIO	N RELAT	TED TO:	11. INSURED	'S POLIC'	Y GROU	P OR FE	CA NUI	MBER		
a. OTHER IN	SURED'	S POLIC	Y OR G	ROUP	NUMBE	3		a. EMP	LOYMENT?	(Current o	r Previo	us)	a. INSURED'S	DATE O	ғ віңтн				SEX	
b. RESERVI	D FOR	illee u	SE.					L AUT	O ACCIDEN	rES [NO			1 1			м[
o. ricoerivi	OR I	.500 0						U. AUT		rES [NO P	LACE (State)	b. OTHER CL	AIM ID (D	resignate	a by NU	iCC)			
c. RESERVE	D FOR N	IUCC U	BE					c. OTH	ER ACCIDE	NT?	_ ¬мо		c. INSURANC	E PLAN N	NAME OF	R PROG	RAM NA	AME		
d. INSURAN	DE PLAN	NAME	OR PRO	GRAM	NAME			10d. CL	AIM CODE:			IUCC)	d. IS THERE			H BENE	FIT PLA	AN?		
		RE.	AD BAC	K OF F	ORM BE	FORE C	OMPLETIN	G & SIGN	ING THIS F	ORM.			13, INSURED						9, 9a, and URE I au	
12. PATIENT to proces below.	'S OR Al s this clai	JTHORI m. I also	ZED PER request	RSON'S paymen	SIGNA it of gove	TURE 1 a	authorize the enefits either	release or r to myself	f any medica or to the par	al or other in rty who acc	nformatio epts assi	n necessary ignment	payment o services d	f medical	benefits					
SIGNED									DATE				SIGNED							
14 DATE OF				HIPOV	or PREG	NANCY	(LMP) 15.	OTHER	DATE						NABLE 1	TO WOR	IZ BLOL			ATION
10	DI	NT ILLN		DUNT,	011111111111111111111111111111111111111					MM C	D I	YY		W L DD	- 1 Y	y won	IN IIV CC	JRREN'	T OCCUP	ATION
19	U	**	QUAL.			OURCE		JAL. a.		MM C	DD	YY	FROM				то			
17. NAME O	REFER	FING P	QUAL. ROVIDE	RORO	OTHER S		17	а.		ММ С	DD	YY	FROM 18. HOSPITAL MI	JZATION U DD			TO D TO C TO	URRE	NT SERVI	
19. ADDITIC	NAL CLA	RING P IM INFO afasita	QUAL, ROVIDE DRMATIC amab-	ON (Dec	OTHER Signated	by NUCo	177 177 0) 10 mg, 73	a. b. NPI	8-01)>>	мм С	DD	w	FROM 18. HOSPITAL	JZATION U DD			TO D TO C TO		NT SERVI	
19. ADDITIO <smon. 21. DIAGNO</smon. 	NAL CLA	RING P IM INFO afasita	QUAL. ROVIDE ORMATIC amab-	ON (Der CXIX),	OTHER Signated	by NUCCion, 20	17/ 17/ 0) 10 mg, 73	a. b. NPI 8535-20 vice line b		ICD Inc			FROM 18. HOSPITAL FROM 20. OUTSIDE YES 22. RESUBM	JZATION U DD	DATES	RELATE	TO TO TO \$ CH	URRE	NT SERVI	
19. ADDITIO <smon. 21. DIAGNO</smon. 	NAL CLA	RING P IM INFO afasita	QUAL. ROVIDE ORMATIC amab-	ON (Dec	OTHER Signated	by NUCCion, 20	177 177 0) 10 mg, 73	a. b. NPI	8-01)>>			2	18. HOSPITAL FROM 20. OUTSIDE YES 22. RESUBMI	JZATION DD	DATES NO 2		TO TO TO \$ CH	URREI MM IARGE:	NT SERVI	
7. NAME O 19. ADDITIO	NAL CLA NAL CLA IUVI (t SIS OR I Code	IRING P	QUAL. ROVIDE DRMATIC amab- OF ILLI F. J. VICE	ON (Der CXIX),	Signated Infusion Injus	by NUCCion, 20	17. 17. 17. 10 mg, 73 e A-L to sen 24 G. L K. L	a. b. NPI B535-20 vice line b	8-01)>> alow (24E)	ICD Inc		2.	FROM 18. HOSPITAL FROM 20. OUTSIDE YES 22. RESUBMI 4. E 23. PRIOR AL	JZATION DD LAB? SSION	DATES NO 2	RELATE	TO TO CO	URREI MM IARGE:	IT SERVI	ICES
7. NAME O 19. ADDITIO	NAL CLUVI (to Els on in Code	IRING P IM INFO afasita IATURE DF SER	QUAL. ROVIDE DRMATIC	ON (Der CXIX),	Signated Infusion Injur	by NUCC ion, 20 BY Relat	17. 17. 17. 10 mg, 73 e A-L to sen 24 G. L K. L	a. b. NPI 3535-20 vice line b D 2	8-01)>> slow (24E) SERVICES, al Circumsta	ICD Inc		2	FROM 18. HOSPITAL FROM 20. OUTSIDE YES 22. RESUBMI 4. E 23. PRIOR AL	JZATION JDD LAB?	DATES NO 2	RELATE 4 (TO TO CO	URREI MM IARGE:	NT SERVI	ICES YY
7. NAME O 19. ADDITIO	NAL CLUVI (to Esis on in Code ATE(S): YY 152080	IRING P IM INFO afasita IATURE DF SER	QUAL. ROVIDE DRMATIC amab- OF ILLI F. J. VICE To	ON (Der CXIX),	Signated Infusion INJUR A-E	by NUCCion, 20	177. 177 178 10 mg, 73 10 AL to sen 24 G. L K. L D. PROCE (Expl	a. b. NPI S535-20 vice line b	8-01)>> slow (24E) SERVICES, al Circumsta	ICD Inc D H L , OR SUPFances)		E. DIAGNOSIS	FROM 18. HOSPITAL FROM 20. OUTSIDE YES 22. RESUBM 4 E 23. PHIOR AL	JZATION JDD LAB?	DATES NO 2	RELATE 4 (UMBEH H. PROT Family Flain	TO TO CO S CH	URREI MM IARGE:	J. RENDE	ICES YY
19. ADDITIC <mon. 124.="" 21.="" <n47350="" a.="" dd="" dd<="" de="" diagno="" dx="" e.="" from="" l.="" mm="" td=""><td>NAL CLUVI (to Esis OR In Code ATE(S) YY 152080</td><td>IRING POLITICATION IN THE INTERIOR IN</td><td>OUAL. ROVIDE DRMATICA Amabo OFILL F. J. VICE To DD 15>> DD</td><td>ON (Decoxix),</td><td>Signated Infusion Inf</td><td>by NUCCion, 20</td><td>17. 17. 17. 17. 17. 17. 17. 17. 17. 17.</td><td>B535-20 B535-20 BDURES, ain Unusuecs</td><td>8-01)>> alow (24E) SERVICES, al Circumsta</td><td>ICD Inc D H L , OR SUPFances)</td><td></td><td>DIAGNOSIS POINTER</td><td>FROM MINE THE PROPERTY OF THE</td><td>JZATION JDD LAB?</td><td>DATES NO G. DAYS OR UNITS</td><td>PELATE H. PROT Family Flan</td><td>TO TO TO S CH I. ID. GUAL. NPI</td><td>URREI MM IARGE:</td><td>J. RENDE</td><td>ICES YY</td></mon.>	NAL CLUVI (to Esis OR In Code ATE(S) YY 152080	IRING POLITICATION IN THE INTERIOR IN	OUAL. ROVIDE DRMATICA Amabo OFILL F. J. VICE To DD 15>> DD	ON (Decoxix),	Signated Infusion Inf	by NUCCion, 20	17. 17. 17. 17. 17. 17. 17. 17. 17. 17.	B535-20 B535-20 BDURES, ain Unusuecs	8-01)>> alow (24E) SERVICES, al Circumsta	ICD Inc D H L , OR SUPFances)		DIAGNOSIS POINTER	FROM MINE THE PROPERTY OF THE	JZATION JDD LAB?	DATES NO G. DAYS OR UNITS	PELATE H. PROT Family Flan	TO TO TO S CH I. ID. GUAL. NPI	URREI MM IARGE:	J. RENDE	ICES YY
19. ADDITIC	NAL CLUVI (to Esis OR In Code ATE(S) YY 152080	IRING P IM INFO afasita IATURE DF SERI	OUAL. ROVIDE DRMATICA MAD- OF ILL F. J. VICE To DD 15>>	ON (Decoxix),	Signated Infusion INJUR A-E B. PLACE O	by NUCCion, 20	177. 177. 177. 177. 178. 100 mg, 73 100 mg,	B535-20 B535-20 BDURES, ain Unusuecs	8-01)>> alow (24E) SERVICES, al Circumsta	ICD Inc D H L , OR SUPFances)		E. DIAGNOSIS POINTER	FROM 18. HOSPITAL FROM 20. OUTSIDE YES 222. RESUBMI 4 E 23. PHIOR AL 5. S CHARG	JZATION JDD LAB?	NO 2	PELATE H. PROT Family Flan	TO TO S CH	URREI MM IARGE:	J. RENDE	ICES YY
19. ADDITIC (>MON. 21. DIAGNO A L DX E. L. 124. A. C. (>NMM DD MM DD MM DD MM DD MM DD	NAL CLUVI (to Esis OR In Code ATE(S) YY 152080	IRING POLITICATION IN THE INTERIOR IN	OUAL. ROVIDE DRMATICA Amabo OFILL F. J. VICE To DD 15>> DD	ON (Decoxix),	Signated Infusion Inf	by NUCCion, 20	17. 17. 17. 17. 17. 17. 17. 17. 17. 17.	B535-20 B535-20 BDURES, ain Unusuecs	8-01)>> alow (24E) SERVICES, al Circumsta	ICD Inc D H L , OR SUPFances)		DIAGNOSIS POINTER	FROM MINE THE PROPERTY OF THE	JZATION JDD LAB?	DATES NO G. DAYS OR UNITS	H. PSOT Ramby	TO TO TO S CH I. ID. GUAL. NPI	URREI MM IARGE:	J. RENDE	ICES YY
19. ADDITIC	NAL CLUVI (to Esis OR In Code ATE(S) YY 152080	IRING POLITICATION IN THE INTERIOR IN	OUAL. ROVIDE DRMATICA Amabo OFILL F. J. VICE To DD 15>> DD	ON (Decoxix),	Signated Infusion Inf	by NUCCion, 20	17. 17. 17. 17. 17. 17. 17. 17. 17. 17.	B535-20 B535-20 BDURES, ain Unusuecs	8-01)>> alow (24E) SERVICES, al Circumsta	ICD Inc D H L , OR SUPFances)		DIAGNOSIS POINTER	FROM MINE THE PROPERTY OF THE	JZATION JDD LAB?	DATES NO G. DAYS OR UNITS	RELATE A (OUMBER H. PROOF) Run PROOF	TO TO TO C S CH I. ID. GUAL. NPI NPI	URREI MM IARGE:	J. RENDE	ICES YY
19. ADDITIC (>MON. 21. DIAGNO A L DX E. L. 124. A. C. (>NMM DD MM DD MM DD MM DD MM DD	NAL CLUVI (to Esis OR In Code ATE(S) YY 52080	IRING POLITICATION IN THE INTERIOR IN	OUAL. ROVIDE DRMATICA Amabo OFILL F. J. VICE To DD 15>> DD	ON (Decoxix),	Signated Infusion Inf	by NUCCion, 20	17. 17. 17. 17. 17. 17. 17. 17. 17. 17.	B535-20 B535-20 BDURES, ain Unusuecs	8-01)>> alow (24E) SERVICES, al Circumsta	ICD Inc D H L , OR SUPFances)		DIAGNOSIS POINTER	FROM MINE THE PROPERTY OF THE	JZATION JDD LAB?	DATES NO G. DAYS OR UNITS	RELATE H. PROT Fasily Rus	TO TO TO S CH	URREI MM IARGE:	J. RENDE	ICES YY
P. NAMEO 19. ADDITIC 19. ADDI	NAL CLUVI (to Esis OR In Code ATE(S) YY 52080	IRING POLITICATION IN THE INTERIOR IN	OUAL. ROVIDE DRMATICA Amabo OFILL F. J. VICE To DD 15>> DD	ON (Decoxix),	Signated Infusion Inf	by NUCCion, 20	17. 17. 17. 17. 17. 17. 17. 17. 17. 17.	B535-20 B535-20 BDURES, ain Unusuecs	8-01)>> alow (24E) SERVICES, al Circumsta	ICD Inc D H L , OR SUPFances)		DIAGNOSIS POINTER	FROM MINE THE PROPERTY OF THE	JZATION JDD LAB?	DATES NO G. DAYS OR UNITS	A ()	TO TO TO S CH II. ID. GUAL. NPI NPI NPI NPI NPI	URREI MM IARGE:	J. RENDE	ICES YY
7. NAME 0 19. ADDITIC <	F REFER	IRING P IRING	QUAL. ROVIDE DRMATK DRMATK DRMATK F. J. J. DD DD DD DD	DN (Deccxix), NESS C	Signated Infusion Inf	B C. EMG	17. 17. 17. 17. 17. 17. 17. 17. 17. 17.	a, b, NPI BSS55-20 BD 2 BD 2 BD 3 BD	8-01)>> alow (24E) SERVICES, al Circumsta Mr	ICD IncD IncD IncD IncD IncD IncD IncD Inc	J. L.	DIAGNOSIS POINTER A A	FROM MINE THE PROPERTY OF THE	UZATION WILLIAM DO NOT THE CONTROL OF T	DATES Y	A ()	TO TO S CH	DURREE MM HARGES	J. RENDE	ERING ERID. #
19. ADDITIC SMON. 21. DIAGNO A. L DX E. L. I. L. 24. A. L. MM DC	F REFERENCE OF THE PROPERTY OF	IRING P IRING	QUAL. ROVIDED RMATIK ROVIDED RMATIK RM DD RMATIK RM DD DD DD	ON (Decoxity), NESS C	DTHER Signated Infusion Infusi	B C. C. EMG	177 177 177 177 177 177 177 177 177 177	a, b, NPI S535-20 D D S535-20 S535	SERVICES. SERVICES And Circumstant Mr. In No.	ICD Inc D H L L OR SUPPRISON OOD OF ER 27. ACC 70.70 YES	J. LUES	DIAGNOSIS POINTER	FROM MILES AND	JUZATION WILLIAM TO THE	DATES Y	RELATE H. PROPINE RISE PROPINE RISE AMOUNT AMOUN	TO TO S CH	DURREE MM HARGES	J. J. PROVIDE	ERING ERID. #
7. NAMEO 19. ADDITIC <	F REFERENCE OF THE PRINCE OF T	IRING PHYSICI	QUAL. ROVIDED RMATIK ROVIDED RMATIK RM D FILL F, J, D D D D D D D D D D D D D D D D D D	PROPRIES COCXIX), NESS COCXIX), NESS COCXIX,	DTHER Signated Infusion Infusi	B C. C. EMG	17. 177 170 100 mg, 73	a, b, NPI S535-20 D D S535-20 S535	SERVICES. SERVICES And Circumstant Mr. In No.	ICD Inc D H L L OR SUPPRISON OOD OF ER 27. ACC 70.70 YES	J. LUES	E. E. DIAGNOSIS POINTER A A	FROM MI 18. HOSPITAL 18. HOSPIT	JUZATION WILLIAM TO THE	DATES Y	RELATE H. PROPINE RISE PROPINE RISE AMOUNT AMOUN	TO TO S CH	DURREE MM HARGES	J. J. PROVIDE	ERING ERID. #
7. NAMEO 19. ADDITIC <	F REFER	IRING P IRING	QUAL. ROVIDE DRMATK DRMATK DRMATK F. J. J. J. DD DD DD DD	DN (Deccxix), NESS C	DTHER Signated Infusion Injustice A-E	B C. EMG	17. 177 170 100 mg, 73	a, b, NPI BSS55-20 BD 2 BD 2 BD 3 BD	8-01)>> alow (24E) SERVICES, al Circumsta Mr	ICD Inc D D H L L OS SUPPORT Annoce) OOOIFIER	LUES TASSET	DIAGNOSIS POINTER A A	FROM MI 18. HOSPITAL 18. HOSPIT	UZATION WILLIAM DO NOT THE CONTROL OF T	DATES Y	RELATE UUMBER H. H	TO TO S CH	DURREE MM HARGES	J. J. PROVIDE	

CPT°, Current Procedural Terminology; HCPCS, Healthcare Common Procedure Coding System; ICD-10-CM, International Classification of Diseases, Tenth Revision, Clinical Modification; NDC, National Drug Code.

*Always refer to specific payer policies as billing requirements may vary by payer, including use of the 10- or 11-digit NDC.



MONJUVI Example CMS-1450 Claim Form

Physician Office Setting

This example form is provided for guidance and reference only.

MONJUVI and the associated services delivered by institutional providers in a physician office setting are billed on the CMS-1450 Claim Form. It is always the provider's responsibility to determine the appropriate healthcare setting and to submit true and correct claims for the products and services rendered. Incyte cannot guarantee payment of any claim and providers should contact third-party payers for specific information on their coding, coverage, and payment policies as needed.

Box 42

List the appropriate revenue code for each service provided. Drugs billed with HCPCS codes usually require revenue code 0636 (drugs requiring detailed coding)

Box 43

Enter a description for each revenue code

If NDC reporting is required, include the following*:

N4+11-Digit NDC+ML+Unit quantity administered

Box 44

Enter the appropriate HCPCS, modifier, and CPT® codes. For example:

- ▶ Drug J9349 (Injection, tafasitamab-cxix, 2 mg)
- ▶ Modifier
 - JZ (Include the JZ modifier on the same line as the HCPCS code to indicate no amount of drug was discarded)
 - JW (Include the JW modifier on a separate line as the HCPCS code to indicate amount of drug discarded)
- Administration 96413 (Chemo infusion for 1st hour, single or initial drug)

Box 45

Enter the date of service


Box 46

Enter number of units for each line item

- ▶ J9349 billing unit = 2 mg
- ► Single-dose vial = 200 mg
- 200 mg vial = 100 Units

Box 67

Enter the ICD-10-CM diagnosis code



^{*}Always refer to specific payer policies as billing requirements may vary by payer, including use of the 10- or 11-digit NDC.

CPT®, Current Procedural Terminology; HCPCS, Healthcare Common Procedure Coding System; ICD-10-CM, International Classification of Diseases, Tenth Revision, Clinical Modification; NDC, National Drug Code.



| Provider Readiness - Process & Tips

When preparing to treat a patient with MONJUVI for follicular lymphoma (FL), consider the steps below to facilitate patient access, proper claims submission, and appropriate reimbursement. For questions or support on any of these steps, please reach out to IncyteCARES for MONJUVI at **1-855-452-5234** or visit **HCP.IncyteCARES.com/MONJUVI** to complete an enrollment form.

- Research and understand patient-specific benefits and coverage for MONJUVI
- If there are access concerns, be sure to **enroll your patient** in IncyteCARES to understand potential financial assistance options that may be available for eligible patients
- 3 Schedule the patient for their first MONJUVI infusion
- 4 Purchase MONJUVI (if not already in inventory) through one of the following specialty distributors:

Specialty Distributors







Prescribers who do not wish to use buy-and-bill should check with their preferred specialty pharmacy for availability. Specialty pharmacies may obtain access to MONJUVI through the specialty distributors listed above.

After treatment, **complete and submit a claim** to the payer, including all necessary information. If no product was discarded, include the JZ modifier to attest to no wastage. If product was discarded, include the JW modifier to provide the amount discarded.

If you have questions about this process,

IncyteCARES and your Field Access Manager may be able to help.



Access more information online at HCP.IncyteCARES.com/MONJUVI



Call 1-855-452-5234, M-F, 8 AM to 8 PM ET



IncyteCARES for MONJUVI

Patient Support Program Overview

When You Enroll a Patient, an IncyteCARES for MONJUVI Representative Will:

- Call your patient to welcome them and explain their insurance coverage for MONJUVI
- Assess your patient's eligibility for savings or financial assistance programs,* and help them enroll
- Explain the additional support and resources available to them during treatment

^{*}Terms and conditions apply. Program terms may change at any time.





IncyteCARES Supports Your Eligible Patients With Follicular Lymphoma During Treatment With MONJUVI

Our mission is to help patients start and stay on therapy by assisting with access and as-needed support.



For Eligible Patients With Commercial Health Insurance IncyteCARES for MONJUVI Savings Program

Eligible patients can receive MONJUVI for as little as



subject to certain limits[†]

To qualify, patients must:

- ► Have commercial healthcare coverage. Patients insured under federal or state government healthcare programs—including Medicare Part B, Medicare Advantage, Medicaid, TRICARE, or any state medical or pharmaceutical assistance program—are not eligible. Patients without healthcare coverage are also not eligible
- ▶ Be a resident of the United States or Puerto Rico
- ► Have a valid prescription for MONJUVI for an FDA-approved use

*Uninsured, cash-paying, or Alternate Funding Program (AFP) patients are not eligible. Not valid for patients insured through Medicare Part B, Medicare Advantage, Medicaid, TRICARE, or any state medical or pharmaceutical assistance program. Patient enrollment in a copay adjustment program, such as a maximizer or accumulator program, may impact the value of this offer. Annual benefit maximum applies, as may other restrictions. Program benefit applies to medication cost only and does not cover any costs to administer the medication. Valid prescription for MONJUVI® (tafasitamab-cxix) for an FDA-approved indication or compendia-recognized use is required. Please see the full **Patient Terms and Conditions** or call IncyteCARES for MONJUVI at 1-855-452-5234. Update effective as of May 1, 2024.



IncyteCARES for MONJUVI

Patient Support Program Overview (CONT'D)

Enroll Your Eligible Patients in IncyteCARES for MONJUVI

Completing the enrollment form takes about 15 minutes.

Simply download and complete the form, then fax it to 1-866-870-6341.



Visit HCP.IncyteCARES.com/MONJUVI for more information



Enrolled IncyteCARES patients have other financial assistance and support options

When you enroll your patient in IncyteCARES for MONJUVI, we will also review their eligibility for the following programs:



For Eligible Patients
Who Are Uninsured or
Underinsured for MONJUVI

IncyteCARES for MONJUVI Patient Assistance Program



For All Patients

Information About Nonprofit or Other Support Organizations

The IncyteCARES Team Is Available by Phone Every Weekday



Call 1-855-452-5234, M-F, 8 AM to 8 PM ET
Visit HCP.IncyteCARES.com/MONJUVI to learn more



IMPORTANT SAFETY INFORMATION

Warnings and Precautions: (cont'd)

• Embryo-Fetal Toxicity. Based on its mechanism of action, MONJUVI may cause fetal B-cell depletion when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus and women of reproductive potential to use effective contraception during treatment with MONJUVI and for 3 months after the last dose. The combination of MONJUVI with lenalidomide and rituximab is contraindicated in pregnant women. Refer to the lenalidomide prescribing information on use during pregnancy.

Adverse Reactions:

The most common adverse reactions (\geq 20%) in patients with FL receiving MONJUVI were respiratory tract infections (56%) (including COVID-19 infection and pneumonia), diarrhea (38%), rash (37%), fatigue (34%), constipation (29%), musculoskeletal pain (24%), and cough (21%). The most common Grade 3 or 4 laboratory abnormalities (\geq 20%) were decreased neutrophils (48%) and decreased lymphocytes (22%).

Please see the full Prescribing Information for more information about MONJUVI.



